TBWCX
Price
$22.13
Change
+$0.24 (+1.10%)
Updated
Jun 2 closing price
Net Assets
470.99M
VTIAX
Price
$46.73
Change
+$0.28 (+0.60%)
Updated
Jun 2 closing price
Net Assets
629.15B
Interact to see
Advertisement

TBWCX vs VTIAX

Header iconTBWCX vs VTIAX Comparison
Open Charts TBWCX vs VTIAXBanner chart's image
TBWCX vs VTIAX Comparison Chart in %
View a ticker or compare two or three
VS
TBWCX vs. VTIAX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TBWCX is a Hold and VTIAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VTIAX has more cash in the bank: 629B vs. TBWCX (471M). VTIAX pays higher dividends than TBWCX: VTIAX (2.63) vs TBWCX (0.33). TBWCX was incepted earlier than VTIAX: TBWCX (11 years) vs VTIAX (16 years). TBWCX (2.62) is less costly to investors than VTIAX (0.09). TBWCX is a more actively managed with annual turnover of: 39.30 vs. VTIAX (4.00). VTIAX has a lower initial minimum investment than TBWCX: VTIAX (3000) vs TBWCX (5000). VTIAX annual gain was more profitable for investors over the last year : 29.03 vs. TBWCX (11.04). VTIAX return over 5 years is better than : 35.27 vs. TBWCX (9.34).
TBWCXVTIAXTBWCX / VTIAX
Total Expense Ratio1.950.092,167%
Annual Report Gross Expense Ratio2.620.092,911%
Fund Existence11 years16 years-
Gain YTD3.01214.65121%
Front LoadN/AN/A-
Min. Initial Investment50003000167%
Min. Initial Investment IRAN/AN/A-
Net Assets471M629B0%
Annual Yield % from dividends0.332.6312%
Returns for 1 year11.0429.0338%
Returns for 3 years34.8859.4859%
Returns for 5 years9.3435.2726%
Returns for 10 years77.89104.4075%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LIQT1.160.11
+10.07%
LiqTech International
MTUS20.360.80
+4.09%
Metallus
VEON55.300.21
+0.38%
VEON Ltd
RYAAY58.72-0.64
-1.08%
Ryanair Holdings plc
GALT2.42-0.19
-7.28%
Galectin Therapeutics